Could U.S./EU Trade Pact Let Pharma Fight EU Drug Cost Controls In Court?
This article was originally published in The Pink Sheet Daily
Executive Summary
As the European Union and the U.S. reopen talks over the Transatlantic Trade and Investment Partnership (TTIP), opponents warn its so-called Investor-State Dispute Settlement mechanism could be exploited by pharmaceutical groups, undermining efforts by member states to control their drug spending.